On October 9, 2025, Biotyx Medical (Shenzhen) Co., Ltd. completed its first implantation in Argentina of its innovative IBS Angel™ Iron-Based Bioresorbable Scaffold System ("IBS Angel™"), independently developed by the company. Dr. Alejandro Peirone led the implantation at the Hospital De Niños de la Santísima Trinidad in Córdoba, Argentina. This product, which has received local regulatory approval, marks the first successful commercialisation of Biotyx's iron-based bioresorbable material platform in Latin America.
(Source: Pic from Siprotec LinkedIn Page)
The IBS Angel™Iron-Based Bioresorbable Scaffold is the first bioresorbable pediatric pulmonary vascular stent, offering an innovative solution that combines effectiveness, safety, and adaptability for children with congenital heart disease. The mechanical properties and clinical handling of the IBS Angel™ are comparable to those of mainstream cobalt-chromium alloy permanent stents on the market. The scaffold matrix is made of a high-strength, high-ductility, high-purity nitrided iron tube. The scaffold features an ultra-thin strut thickness with strong support and is compatible with sheaths as small as 4F (inner diameter approximately 1.35 mm), allowing easy access to the tiny blood vessels of newborns and infants. After implantation, the IBS Angel™ effectively supports the ductus arteriosus (DA), preventing closure and providing pulmonary blood flow to promote growth. Three to four months after implantation, the scaffold begins to degrade gradually. This decomposition significantly reduces the difficulty of subsequent surgical repair and vascular repair. If the child's heart and lungs are well developed, the ductus arteriosus can naturally close after scaffold degradation, eliminating the need for scaffold removal and potentially avoiding surgical repair. The IBS Angel™ offers an ideal solution for newborns and young infants with ductus arteriosus-dependent disease.
